Collins Stewart

According to a research report published today by Collins Stewart, Ziopharm Oncology's (NASDAQ: ZIOP) palifosfamide endured a positive interim OS trend. Collins Stewart reported, “Final OS data is expected at a medical meeting in 2H12. While we continue to believe the ongoing P3 PICASSO-3 study...

In a recent research report, Collins Stewart reiterated its Neutral rating and $40 PT on Rovi Corporation (NASDAQ: ROVI) as no meaningful catalysts for the stock have appeared near-term. In the report, Collins Stewart said, “We continue to see TotalGuide CE & STB to ultimately be meaningful...

According to a research report published today by Collins Stewart, NetApp Inc. (NASDAQ: NTAP) will report its January quarter this Wednesday after market close. In the report, Collins Stewart noted that, “e. The company's results have been below Street expectations three of the past four quarters...

Collins Stewart reiterates its Buy rating on LinkedIn (NASDAQ: LNKD) and raises its price target to $95 from $86 a share on a wide-margin beat to Q4 earnings and higher-than-expected guidance for next quarter. Collins Stewart says, "We are raising our 2012 EPS estimates by $0.14 to reflect latest...

According to Collins Stewart, First Solar (NASDAQ: FSLR) is downgraded to Neutral. Collins Stewart said that FSLR announced last evening that due to a construction permit issue, the Department of Energy loan approved for its Antelope Valley Solar Ranch One (AVSR) project has not been funded. “...

According to Collins Stewart, Arris Group (NASDAQ: ARRS) is upgraded to Buy. Collins Stewart said that despite inline results/guidance and disappointing results from Moxi (Gateway STBs), it is upgrading the stock to a BUY rating and $15 PT. “We remain convicted that ARRS stands to benefit...